News
Explore the latest stories and publications from NCATS and our partners, see upcoming events, or explore the variety of resources we provide to better understand translational science and our work.
News
Read the latest news from NCATS and its collaborators whose research is supported through the Center’s programs, or follow coverage of NCATS' translational research activities through national and local media.
Paving the Way for Ultrarare Bone Disease Treatment Trial
May 21, 2024 - NCATS News
- Our Impact on Drug Discovery and Development
- Therapeutics for Rare and Neglected Diseases (TRND)
Clinicians at the NIH Clinical Center will soon start testing an investigative drug for an ultrarare bone disease.
Read Article
NCATS Enables a Drug’s Path to FDA Approval for Duchenne Muscular Dystrophy
March 15, 2024 - NCATS News
- Our Impact on Drug Discovery and Development
- Our Impact on Rare Diseases
- Therapeutics for Rare and Neglected Diseases (TRND)
NCATS scientists conducted laboratory studies and provided guidance in the development of a drug for the rare muscle disease Duchenne muscular dystrophy.
JAMA Neurology Publishes Positive Pivotal Clinical Trial with Vamorolone in Duchenne Muscular Dystrophy
September 1, 2022 - Media Coverage
- Therapeutics for Rare and Neglected Diseases (TRND)
Rare Disease Day 2022 – A Day to Embrace Innovation (and Wear Your Stripes)
February 26, 2022 - Media Coverage
- Genetic and Rare Diseases (GARD) Information Center
- Rare Diseases Clinical Research Network (RDCRN)
- Therapeutics for Rare and Neglected Diseases (TRND)
Know All About Rare Disease, Causes And Characteristics
February 26, 2021 - Media Coverage
- Genetic and Rare Diseases (GARD) Information Center
- Rare Diseases Clinical Research Network (RDCRN)
- Therapeutics for Rare and Neglected Diseases (TRND)
NCATS, NRL Create Nanoparticle SARS-CoV-2 Model to Speed Drug Discovery for COVID-19
September 18, 2020 - NCATS News
- Therapeutics for Rare and Neglected Diseases (TRND)
A team of scientists from NCATS and the Naval Research Laboratory (NRL) in Washington, D.C., developed a new tool that mimics how SARS-CoV-2 — the virus that causes COVID-19 — infects a cell, infor